Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...

GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...

GlaxoSmithKline is to team up with two UK ... is just one of a new generation of public-private partnerships in drug discovery being set up across the world. But the scale and depth of this ...

GSK has licensed a small molecule for Parkinson's and is teaming up on additional targets for the disease and another ...

Called the Cambridge-GSK Translational Immunology Collaboration (CG-TIC), the partnership will build on GSK and Cambridge’s existing relationship to find new ways to use existing treatments and ...

I am not implying that the programs from the Generation Bio partnership could offset any potential losses from the GSK partnership, but it is an example of other opportunities that Moderna could ...

GSK acquired an experimental therapy from Chimagen Biosciences, paying $300 million upfront for the “T-cell engager” therapy, ...

GSK has announced a £50m ($54.3m) investment in a new partnership with the University of Cambridge and Cambridge University ...

GSK GSK-1.51%decrease; red down pointing triangle cut its full-year vaccine sales outlook after key shots for respiratory syncytial virus and shingles missed expectations in the third quarter due ...

The Federal Government is advancing its commitment to ensure a self-sustaining healthcare system by collaborating with ...

Despite legal and regulatory challenges, GSK's strategic partnerships and international expansion, particularly in China, enhance its growth potential. GSK stock's valuation remains attractive ...